Original Article
Clinical investigation of taking Cervista high-risk human Papilloma virus DNA test and cytological test in the same sample
Min Wu, Hua Wang, Yingping Gong, Yinglan Wu, Ting Han, Yunhong Zhu, Qiong Xie, Min Xiong, Hong Shi
Published 2016-01-20
Cite as J Chin Physician, 2016, 18(1): 42-46. DOI: 10.3760/cma.j.issn.1008-1372.2016.01.013
Abstract
ObjectiveTo explore the feasibility of taking Cervista high-risk human Papilloma virus DNA (Cervista HR HPVDNA) test and Thinprep cytologic test in the same sample, and to assess the availability and significance of Cervista HR HPVDNA in detecting HPV infection in people, also to study the correlation of Cervista A9 group with high grade cervical dysplasia and the value of HPV16/18 in diagnosing cervical dysplasia.
MethodsTotally 148 cases diagnosed in gynecology clinic during March to April, aging 20 to 65, cytological test ≥ASCUS (atypical squamous cells undetermined significance) were involved in the investigation group, and 153 cases with normal cytological test at the same time were involved in the control group. Cytological test and Cervista high-risk human Papilloma virus DNA test were implemented at the same time on two groups, cases with one of the test method tested abnormal were further biopsied under the colposcope if necessary.
ResultsCervista HR HPVDNA infection rate was 83.78% in the investigation group and 18.30% in the control group with statistic difference (P<0.05). Based on criteria of histology and pathology, Cervista HR HPVDNA infection rate was 81.69% in no cervical intraepithelial neoplasia (CIN), 71.43% in CINⅠ, 90.00% in CINⅡ, 88.89% in CINⅢ and 100.00% in cervical carcinoma without significant difference (Fisher exact Test P>0.05). We further founded that A9 group take the large proportion of Cervista HR HPVDNA infection, and co-infection by 2 or 3 genotypes tested in part grades and A9 group related with Pathology≥CINⅡ(P<0.05). The sensitivity, specificity, positive-predictive value and negative-predictive value of Cervista HR HPVDNA for detecting all cases of CINⅡ were 90.9%, 18.1%, 22.7%, and 88.2%, respectively. A portion (30.6%) of the Cervista HR HPVDNA positive cases showed HPV16/18 positive, while none showed in the Cervista HR HPVDNA negative cases. HPV16/18 infection rate in normal, CINⅠ, CINⅡ, CINⅢ, and Cervical carcinoma were 13.33%, 37.50%, 50.00%, 75%, and 100% with significant difference(Fisher exact Test P<0.05).
ConclusionsCervista HR HPVDNA test was feasible as an Cervical carcinoma screening method. The method of combining Cervista HR HPVDNA test with cytological test in the same sample deserves promotion as its easy operating and definite effect.
Key words:
Biopsy; Uterine cervical neoplasms/DI; Papillomaviridae/ME
Contributor Information
Min Wu
Department of Obstetrics and Gynecology, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Hua Wang
Department of Genetic Service, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Yingping Gong
Department of Obstetrics and Gynecology, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Yinglan Wu
Department of Women's Health Care, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Ting Han
Department of Women's Health Care, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Yunhong Zhu
Department of Laboratory, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Qiong Xie
Department of Genetic Service, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Min Xiong
Department of Comprehensive Treatment Division, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
Hong Shi
Department of Pathology, Hunan Provincial Maternal and Child Healthcare Hospital, Changsha 410008, China
